(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 March 2018 (08.03.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/039810 A1

(51) International Patent Classification:
C12N 5/0775 (2010.01) *A61K 35/28* (2015.01)
C12N 5/077 (2010.01)

(21) International Application Number:
PCT/CH2017/000080

(22) International Filing Date:
29 August 2017 (29.08.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1109/16 29 August 2016 (29.08.2016) CH

(71) Applicant: **PDI PHARM DEVELOPMENT INTERNATIONAL AG** [CH/CH]; Bahnhofstrasse 4, 6052 Hergiswil (CH).

(72) Inventor: **ORLOWSKI, Wojciech**; u. Boleslawa Szczodrego 20/7, 92 414 Lodz (PL).

(74) Agent: **E. BLUM & CO. AG**; Vorderberg 11, 8044 Zürich (CH).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

WO 2018/039810 A1

(54) Title: PROVISION OF A THERAPEUTICALLY ACTIVE CELL PRODUCT

Figure 7.1



(57) Abstract: A therapeutically active cell product and an ex vivo method for preparing it from a tissue donation are provided. The method comprises an in vitro immuno- depletion of hematopoietic stem cells and cells of hematopoietic lineage. The therapeutically active cell product obtained by the method comprises a portion of non-hematopoietic stem cells comprising non-hematopoietic progenitor [stem] cells, multipotent stem cells and/or pluripotent stem cells. Further aspects include the cell product for therapeutic use, in particular for the treatment of autoimmune and/or neurological disease.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*